Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2015 Sep;21(5):320-33.
doi: 10.1097/PRA.0000000000000092.

Acceptance-based Behavior Therapy for Depression With Psychosis: Results From a Pilot Feasibility Randomized Controlled Trial

Brandon A Gaudiano  1 , Andrew M Busch, Susan J Wenze, Kathryn Nowlan, Gary Epstein-Lubow, Ivan W Miller
Affiliations
Randomized Controlled Trial

Acceptance-based Behavior Therapy for Depression With Psychosis: Results From a Pilot Feasibility Randomized Controlled Trial

Brandon A Gaudiano et al. J Psychiatr Pract. 2015 Sep.

Abstract

Acceptance-based depression and psychosis therapy (ADAPT), a mindfulness/acceptance-based behavioral activation treatment, showed clinically significant effects in the treatment of depression with psychosis in a previous open trial. The goal of the current study was to further test the feasibility of ADAPT to determine the utility of testing it in a future clinical trial, following a stage model of treatment development. Feasibility was determined by randomizing a small number of patients (N=13) with comorbid depression and psychosis to medication treatment as usual plus enhanced assessment and monitoring versus ADAPT for 4 months of outpatient treatment. Both conditions were deemed acceptable by patients. Differences in between-subjects effect sizes favored ADAPT posttreatment and were in the medium to large range for depression, psychosocial functioning, and experiential avoidance (ie, the target mechanism). Thus ADAPT shows promise for improving outcomes compared with medications alone and requires testing in a fully powered randomized trial.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

The authors declare no conflicts of interest.

Figures

Figure 1
Figure 1
Changes in depressive symptoms (Quick Inventory of Depressive Symptomatology-Clinician Rating administered by blind evaluators)
Figure 2
Figure 2
Changes in experiential avoidance (Acceptance and Action Questionnaire-II)
See this image and copyright information in PMC

References

    1. Coryell W, Pfohl B, Zimmerman M. The clinical and neuroendocrine features of psychotic depression. J Nerv Ment Dis. 1984;172:521–528. - PubMed
    1. Gaudiano BA, Dalrymple KL, Zimmerman M. Prevalence and clinical characteristics of psychotic versus nonpsychotic major depression in a general psychiatric outpatient clinic. Depress Anxiety. 2009;26:54–64. - PMC - PubMed
    1. Hafner H. Schizophrenia and depression. European Arch Psychiatry Clin Neurosci. 2005;255:157–158. - PubMed
    1. Coryell W, Leon A, Winokur G, et al. Importance of psychotic features to long-term course in major depressive disorder. Am J Psychiatry. 1996;153:483–489. - PubMed
    1. Gaudiano BA, Young D, Chelminski I, et al. Depressive symptom profiles and severity patterns in outpatients with psychotic versus nonpsychotic major depression. Compr Psychiatry. 2008;49:421–429. - PMC - PubMed

Publication types